Paulash Mohsen
CEO
VT
Vesigen Therapeutics
Vesigen Therapeutics develops a non-viral delivery platform utilizing ARRDC1-Mediated Microvesicles (ARMMs) to transport RNA, proteins, and gene-editing complexes to specific tissues and cell types. This technology addresses the challenges of biodistribution, immunogenicity, and payload capacity that limit the effectiveness of traditional delivery methods.
- Biotechnology
Updated 23 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Product
Problem
Many novel therapeutics, including RNA, proteins, and gene-editing complexes, face delivery challenges due to limitations of existing vehicles like viral vectors and lipid nanoparticles. These challenges include issues with biodistribution, payload capacity, immunogenicity, dose-limiting toxicity, and manufacturing complexity.
Solution
Vesigen Therapeutics is developing a non-viral delivery platform based on ARRDC1-Mediated Microvesicles (ARMMs) to overcome the limitations of traditional delivery methods. The platform enables efficient delivery of various therapeutic payloads, such as RNA, proteins, and gene-editing complexes, to specific tissues and cell types, including those that have been historically difficult to target. ARMMs are engineered by appending a therapeutic payload to the protein ARRDC1, encapsulating it within the vesicle. This approach allows for customizable tissue targeting, a large carrying capacity, efficient delivery across different tissues, and a simplified manufacturing process, while also being immune silent and re-dosable.
Target Audience
The primary target audience includes pharmaceutical and biotechnology companies seeking improved delivery solutions for novel therapeutics, as well as researchers and clinicians developing gene therapies, protein therapeutics, and RNA-based medicines.
Features
- Non-viral delivery platform based on human cell-derived extracellular vesicles called ARMMs
- Engineered ARMMs with customizable tissue targeting capabilities
- Large carrying capacity, capable of delivering gene editors, proteins, and RNA
- Efficient delivery across different tissues with no endosomal trapping
- Immune silent and re-dosable due to human-derived, non-viral components
- Simplified, one-step upstream manufacturing process using off-the-shelf starting materials